2196.HK - Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 20.450 |
| Open | 20.650 |
| Bid | 20.950 x 0 |
| Ask | 21.000 x 0 |
| Day's Range | 20.450 - 21.150 |
| 52 Week Range | 17.360 - 34.000 |
| Volume | |
| Avg. Volume | 2,307,857 |
| Market Cap | 84.946B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | 11.73 |
| EPS (TTM) | 1.790 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.66 (3.23%) |
| Ex-Dividend Date | Jun 08, 2022 |
| 1y Target Est | 32.62 |
Fair Value
Related Research
PR NewswireFosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023 is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196.SH, 02196.HK) has participated in the Expo. Together with Henlius, Fosun Kite, Fosun Health and the in-depth incubation platform Fosun Lead, Fosun Pharma showcases its innovative R&D achievements and globalization footprint in the healthc
PR NewswireFosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative
On April 25, 2023, World Health Organization (WHO) gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement. Within this theme, WHO will mainly focus on the third "i" – implement – and notably the critical importance of reaching hard to reach populations with the tools and strategies that are available today.
PR NewswireFosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the 2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating Expert Committee, for the outstanding performance reported. In 2022, Fosun Pharma was also awarded honors including the "Annual Enterprise of Corporate Social Responsib
PR NewswireFosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement
On March 27, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma" or "the Group", Stock Code: 600196.SH; 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its 2022 annual results today (the "Reporting Period").
ZacksSyneos Health (SYNH) to Launch Serplulimab With New Pact
Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.
GlobeNewswireSyneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial SolutionsMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun Pharma USA Inc. (“Fosun Pharma USA“), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK). As part of the partnership, Syneos Healt
PR NewswireFosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab in the United States (US). This marks an important milestone for Fosun Pharma's development in the US.
- Reuters
BioNTech's COVID booster vaccine approved in Hong Kong for individuals from age 12
BioNTech and its partner for China, Shanghai Fosun Pharmaceutical, were granted approval for their COVID-19 vaccine that is adapted for the BA.4 and the BA.5 subvariants of Omicron for people aged 12 and older in Hong Kong, the German company said on Friday. The vaccine is the first and currently only variant-adapted vaccine available as a booster dose for individuals 12 years and older that has been granted approval in Hong Kong, BioNTech said.
PR NewswireComirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents
On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose Dispersion for Injection COVID-19 mRNA Vaccine (nucleoside modified)) ("Comirnaty bivalent vaccine") by Fosun Pharma/BioNTech arrived in Hong Kong Special Administrative Region of the People's Republic of China
- Reuters
UPDATE 2-German expats in China will have access to BioNTech vaccine, says Scholz
German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany's BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens. On his first visit to China since becoming chancellor and the first by a G7 leader since the pandemic, Scholz said China and Germany had different approaches to fighting the virus but had a joint responsibility to eliminate it.
PR NewswireFosun Pharma's MSCI ESG Rating Upgraded to A
The world's leading index company Morgan Stanley Capital International ("MSCI") recently announced its latest annual Environmental, Social and Governance ("ESG") rating results. In recognition of its outstanding performance in ESG, MSCI upgraded the ESG rating of Fosun Pharma (stock code: 600196.SH, 02196.HK) from BBB to A, ranking the top level in China. Fosun Pharma's MSCI ESG rating has been upgraded from BB in 2020 to BBB in 2021. The continuous upgrade to A this year demonstrates the high r
PR NewswireFosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product
Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid product, which is under an exclusive partnership between Fosun Pharma USA Inc. ("Fosun Pharma USA"), the US-based subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) and MAIA Pharmaceuticals, Inc. (MAIA), a Princeton, NJ based specialty pharmaceutical company,
PR NewswireFosun Pharma Announces 2022 Interim Results
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK), a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China, announced its interim results for the first half of 2022.